Target
Bcl-2-like protein 1
Ligand
BDBM209225
Substrate
n/a
Meas. Tech.
Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET) Assay
Temperature
298.15±n/a K
Ki
<0.1±n/a nM
Comments
extracted
Citation
 Wang, LDoherty, GWang, XTao, ZBruncko, MKunzer, ARWendt, MDSong, XFrey, RHansen, TMSullivan, GMJudd, ASouers, A Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases US Patent  US9266877 Publication Date 2/23/2016 
Target
Name:
Bcl-2-like protein 1
Synonyms:
Anti-apoptotic Bcl-2 protein | Apoptosis Regulator Bcl-xL | Apoptosis regulator Bcl-X | B2CL1_HUMAN | BCL2-like 1 isoform 1 | BCL2L | BCL2L1 | BCLX | Bcl-2-like protein 1 (Bcl-XL) | Bcl-X | Bcl-xL/Bcl-2-binding component 3 | Bcl2-L-1 | Bcl2-antagonist of cell death (BAD)
Type:
Mitochondrion membrane; Single-pass membrane protein
Mol. Mass.:
26039.60
Organism:
Homo sapiens (Human)
Description:
n/a
Residue:
233
Sequence:
MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
  
Inhibitor
Name:
BDBM209225
Synonyms:
US9266877, 171
Type:
Small organic molecule
Emp. Form.:
C37H37N7O4S2
Mol. Mass.:
707.864
SMILES:
Cc1[nH]c(C#N)c(CC2CCCCC2)c1-c1ccc(nc1C(=O)NS(C)(=O)=O)N1CCc2cccc(C(=O)Nc3nc4ccccc4s3)c2C1 |(7.93,2.6,;7.3,4.01,;8.07,5.35,;7.04,6.49,;7.36,8,;7.68,9.5,;5.63,5.86,;4.3,6.63,;4.3,8.17,;2.96,8.94,;2.96,10.48,;4.3,11.25,;5.63,10.48,;5.63,8.94,;5.79,4.33,;4.65,3.3,;5.42,1.97,;4.65,.63,;3.11,.63,;2.34,1.97,;3.11,3.3,;2.34,4.64,;.8,4.64,;3.11,5.97,;2.34,7.3,;1.57,8.64,;1,6.53,;3.67,8.07,;2.34,-.7,;.8,-.7,;.03,-2.03,;.8,-3.37,;.03,-4.7,;.8,-6.03,;2.34,-6.03,;3.11,-4.7,;4.65,-4.7,;5.42,-3.37,;5.42,-6.03,;6.96,-6.03,;7.86,-4.79,;9.33,-5.26,;10.66,-4.49,;12,-5.26,;12,-6.8,;10.66,-7.57,;9.33,-6.8,;7.86,-7.28,;2.34,-3.37,;3.11,-2.03,)|
Structure:
Search PDB for entries with ligand similarity: